Collaborative Education for CAR T-Cell Therapy

Opinion
Video

The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.

CN_TA_MM_Seg09_Collaborative
Current Time 0:00
Duration 4:12
Loaded: 3.90%
Stream Type LIVE
Remaining Time 4:12
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following question:

    • Please provide your final thoughts on the unmet needs and future directions for enhancing the transition of care and fostering stronger partnerships between academic and community settings in the field of CAR T-cell therapy.
    Recent Videos
    4 experts are featured in this series.
    Real World Experience of CAR-T in MM Patients
    4 experts are featured in this series.
    Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
    4 experts are featured in this series.
    Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
    4 experts are featured in this series.
    Future Perspectives: What’s Next in NDMM?
    4 experts are featured in this series.
    Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
    4 experts are featured in this series.
    Jackson’s Journey with High Risk R/R MM
    4 experts are featured in this series.
    Role of Bridging Therapy for CAR-T Patients
    4 experts are featured in this series.
    Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
    4 experts are featured in this series.
    Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
    4 experts are featured in this series.
    Overview of Process of CAR-T Therapy
    Related Content
    Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

    Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

    Roman Fabbricatore
    March 25th 2025
    Article

    Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

    Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

    Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

    Samantha Shenoy, NP, MSN
    October 14th 2024
    Podcast

    Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

    Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

    Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

    Roman Fabbricatore
    March 21st 2025
    Article

    Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

    James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

    Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

    James R. Berenson, MD, FACP
    September 30th 2024
    Podcast

    James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

    Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

    Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

    Tim Cortese
    March 14th 2025
    Article

    Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

    Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

    Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

    ONCOLOGY Staff
    March 9th 2025
    Article

    A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.